Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
BACKGROUND: In the context of recent guidelines on invasive candidiasis (IC), how French intensive care units (ICUs) are managing IC? METHODS: This is a prospective observational multicenter cohort study. During 1 year (2012-2013), 87 French ICUs enrolled consecutive patients with suspected or proven IC (SIC or PIC) and receiving systemic antifungal therapy (SAT). Data were collected up to 28 days after inclusion. RESULTS: We studied 835 patients, 291 with PIC and 544 with SIC. At SAT initiation, patients with SIC were significantly more severe (SAPS II 50.1 ± 18.7 vs. 46.2 ± 18.0). Severe sepsis or septic shock prompted to initiate empiric SAT in 70 % of SIC. Within 4 days in median, the initial SAT was modified in 49 % of patients with PIC vs. 33 % patients with SIC. Modifications were most often motivated by mycological results, and de-escalation was the most frequent change. Regarding compliance to IC management guidelines, echinocandin was used for 182 (62.5 %) patients with PIC, and 287 (52.7 %) of those with SIC; central venous catheter was removed in 87 (54.3 %) of patients with candidaemia, and 43 of the remaining patients received echinocandin; and de-escalation was undertaken after 5 days of SAT in 142 patients, after 10 days in 13 patients. As 20.6 % of SIC were secondarily documented, 403/835 (48 %) patients had finally a proven IC. Candida albicans was the main pathogen (65.3 %), then Candida glabrata (15.9 %). The 28-day mortality rates were 40.0 % in candidaemia, 25.4 % in cIAI, and 26.7 % in deep-seated candidiasis. In the overall population of patients with proven IC, four independent prognostic factors were identified: immunosuppression (Odds Ratio (OR) = 1.977: 1.03-3.794 95 % confidence interval (CI), p = 0.04), age (OR = 1.035; 1.017-1.053 95 % CI; p < 0.001), SAPS >46 on ICU admission (OR = 2.894; 1.81-4.626 95 % CI; p < 0.001), and surgery just before or during ICU stay (OR = 0.473; 0.29-0.77 95 % CI; p < 0.001). CONCLUSION: When SAT is initiated in French ICUs, the IC is ultimately proven for 48 % of patients. Empiric SAT is initiated in severely ill ICU patients. The initial SAT is often adapted, with de-escalation to fluconazole when possible. Mortality rate remains high.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In our investigation, patients treated initially with an echinocandin were more likely to die during their candidemia-associated hospitalization than those treated with fluconazole. However, this finding is likely from confounding factors because critically ill patients are more likely to be treated with an echinocandin [33].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, this finding is likely from confounding factors because critically ill patients are more likely to be treated with an echinocandin [33].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 32 · Cited by 102
Metadata
- Authors
- Leroy, O., Bailly, S., Gangneux, J.-P., Mira, J.-P., Devos, P., Dupont, H., Montravers, P., Perrigault, P.-F., Constantin, J.-M., Guillemot, D., Azoulay, E., Lortholary, O., Bensoussan, C., & Timsit, J.-F.
- Affiliations
- Centre Hospitalier de Tourcoing (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Hôpital Cochin (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Institut Pasteur (FR)
- Hôpital Necker-Enfants Malades (FR)
- MSD (France) (FR)
- Corresponding author
- Leroy, Olivier
- ORCID
- Venue
- Annals of Intensive Care
- Publisher
- Elsevier BV
- Published
- 2016
- Volume
- 6
- Issue
- 1
- Pages
- 2
- ISSN
- 2110-5820 (ISSN-L)
- PMC
- PMC4705061
- OpenAlex
- W2234667003
- Cited by
- 102
- References
- 32
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 11 · 2021: 8 · 2020: 13 · 2019: 8 · 2018: 9 · 2017: 15 · 2016: 6
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3610 d)
- Locations
- Annals of Intensive Care (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Pfizer
- Gilead Sciences
- MSD France
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- invasive candidiasis, systemic antifungal therapy, echinocandins, antifungal de-escalation, candidemia, central venous catheter removal, empirical antifungal therapy, septic shock, immunosuppression, prognostic factors, 28-day mortality, intensive care unit management, Candida albicans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. https://app.cochat.ai/papers/10.1186/s13613-015-0103-7
- The paper
- Leroy, O., Bailly, S., Gangneux, J.-P., Mira, J.-P., Devos, P., Dupont, H., Montravers, P., Perrigault, P.-F., Constantin, J.-M., Guillemot, D., Azoulay, E., Lortholary, O., Bensoussan, C., & Timsit, J.-F. (2016). Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Annals of Intensive Care. https://doi.org/10.1186/s13613-015-0103-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
